Efficacy and safety of exenatide once‐weekly vs exenatide twice‐daily in Asian patients with type 2 diabetes mellitus. Issue 1 (14th September 2012)

• Record Type: Journal Article
• Authors: Ji, Linong; Onishi, Yukiko; Ahn, Chul Woo; Agarwal, Pankaj; Chou, Chien‐Wen; Haber, Harry; Guerrettaz, Kelly; Boardman, Marilyn K
• Is Part Of: Journal of diabetes investigation. Volume 4:Issue 1(2013:Feb.)
• Page Start: 53
• Page End: 61
• Publication Date: 2012-09-14
• Subjects: Diabetes -- Periodicals; Diabetes -- Research -- Periodicals; Diabetes Mellitus -- Periodicals; 616.462005
• DOI: 10.1111/j.2040-1124.2012.00238.x
• Languages: English
• ISSNs: 2040-1116

Abstract

<abstract abstract-type="main" id="jdi238-abs-0001"> <title>Abstract</title> <sec id="jdi238-sec-0001" sec-type="section"> <title>Aims/Introduction</title> <p>To compare safety and efficacy of the extended‐release formulation exenatide once weekly (EQW) vs exenatide twice daily (EBID) for 26 weeks in type 2 diabetes patients from China, India, Japan, South Korea and Taiwan.</p> </sec> <sec id="jdi238-sec-0002" sec-type="section"> <title>Materials and Methods</title> <p>A randomized, comparator‐controlled, open‐label study included 681 patients with type 2 diabetes inadequately controlled (hemoglobin A1c [HbA<sub>1c</sub>] ≥7 and ≤11%) with oral antihyperglycemic medications (OAMs). Patients added 2 mg EQW or 10 μg EBID to current OAMs. Safety was re‐evaluated 10 weeks after last treatment.</p> </sec> <sec id="jdi238-sec-0003" sec-type="section"> <title>Results</title> <p>EQW was superior to EBID on HbA<sub>1c</sub> measures at week 26 (Least‐squares mean treatment difference: −0.31% [95% confidence interval −0.49, −0.14%]). More EQW‐treated patients achieved target HbA<sub>1c</sub> ≤7.0% (<italic>P</italic> = 0.003), ≤6.5% (<italic>P</italic> < 0.001), or ≤6.0% (<italic>P</italic> = 0.003). Fasting serum glucose reductions were greater among EQW‐treated patients (<italic>P</italic> < 0.001). Blood glucose profiles improved in both treatment groups (<italic>P</italic> < 0.001). Weight loss occurred with both treatments, but was greater with EBID. Adverse events (≥10%, either group) were nausea, injection‐site induration, dyslipidemia and vomiting. Injection‐site induration was more frequent with EQW, whereas nausea, vomiting and hypoglycemia were less frequent. One episode each of major hypoglycemia (EBID) and pancreatitis (EQW) were reported.</p> </sec> <sec id="jdi238-sec-0004" sec-type="section"> <title>Conclusion</title> <p>In this population, EQW and EBID showed efficacious glucose and weight control; safety and tolerability were consistent with observations in non‐Asian patients. This trial was registered with ClinicalTrials.gov (no. NCT00917267).</p> </sec> </abstract>